Mavoglurant (AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials.
This page contains content from the copyrighted Wikipedia article "Mavoglurant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
